Abstract
The Aβ peptide assembles into a variety of distinct types of structures in vitro and in the brain which have different biological consequences. Differential effects of inhibitory small molecules suggest that a sequential monomer - oligomer - fibril mechanism is overly simplistic and that soluble toxic oligomers and fibrils can be formed in common or separate pathways depending on the local environment. As a result, the effects of inhibitors are often assay-dependent because multiple pathways are operating. This review discusses strategies for teasing apart the intricate protein-protein interactions that result in Aβ assembly.
Original language | English |
---|---|
Pages (from-to) | 185-197 |
Number of pages | 13 |
Journal | Amyloid |
Volume | 14 |
Issue number | 3 |
DOIs | |
State | Published - 2007 |
Bibliographical note
Funding Information:The author received funding by NIH A628816.
Keywords
- Fibril extension
- Fibril nucleation
- Oligomer
- Toxicity
ASJC Scopus subject areas
- Internal Medicine